RhumbLine Advisers’s BioNTech BNTX Stock Holding History

RhumbLine Advisers’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Hold	110	–	–	﹤0.01%	3899
2026 Q1	$9.78K	Hold	110	–	–	﹤0.01%	3811
2025 Q4	$10.5K	Hold	110	–	–	﹤0.01%	3850
2025 Q3	$10.8K	Sell	110 -38	-26%	-$4.06K	﹤0.01%	3847
2025 Q2	$15.8K	Sell	148 -1	-0.7%	-$101	﹤0.01%	3816
2025 Q1	$13.6K	Buy	149 +29	+24%	+$3.25K	﹤0.01%	3789
2024 Q4	$13.7K	Hold	120	–	–	﹤0.01%	3846
2024 Q3	$14.3K	Hold	120	–	–	﹤0.01%	3850
2024 Q2	$9.64K	Hold	120	–	–	﹤0.01%	3985
2024 Q1	$11.1K	Hold	120	–	–	﹤0.01%	3849
2023 Q4	$12.7K	Hold	120	–	–	﹤0.01%	3831
2023 Q3	$13K	Hold	120	–	–	﹤0.01%	3834
2023 Q2	$13K	Buy	+120	New	+$13.5K	﹤0.01%	3886

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

RhumbLine Advisers's BNTX Position: Q2 2026 in Review

RhumbLine Advisers held its BioNTech (BNTX) position steady in Q2 2026 at 110 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3899.

RhumbLine Advisers first reported a position in BNTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $15.8K in Q2 2025. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

RhumbLine Advisers held 110 shares of BioNTech worth $10.2K as of Q2 2026.
RhumbLine Advisers left its BioNTech share count unchanged in Q2 2026.
BioNTech made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3899 holding.
RhumbLine Advisers first reported a position in BioNTech in Q2 2023 and has held it in 13 quarters since.
RhumbLine Advisers's BioNTech position peaked at $15.8K in Q2 2025.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.